Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | RIPK3 | Q9Y572 | 13/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544192 | 0.89 | CASP3 (0.60) | RIPK3RIPK1NPC1RAB9ACASP3 | |
| SCHEMBL4404856 | 0.85 | ABL1 (0.56) | ABL1RIPK3RIPK1NPC1RAB9A | |
| SCHEMBL4402171 | 0.85 | ENPP3 (0.56) | ABL1RIPK3RIPK1NPC1RAB9A | |
| SCHEMBL544191 | 0.85 | LCK (0.60) | ABL1RIPK3RIPK1NPC1RAB9A | |
| SCHEMBL544513 | 0.84 | CASP3 (0.62) | ABL1RIPK3RIPK1NPC1RAB9A | |
| SCHEMBL4402209 | 0.82 | MAPT (0.67) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL4394510 | 0.81 | ENPP3 (0.60) | ABL1NPC1RAB9ACASP3SENP8 | |
| SCHEMBL4404654 | 0.81 | ENPP3 (0.62) | NPC1RAB9ACASP3SENP8SENP7 | |
| SCHEMBL4397027 | 0.80 | ENPP3 (0.53) | RIPK3RIPK1NPC1RAB9ACASP3 | |
| SCHEMBL544153 | 0.79 | MET (0.67) | ABL1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110571-B2 | Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents | AVENTIS PHARMA S.A. (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194555-A1 | Novel Benzimidazole and Benzothiazole Derivatives, Method for Preparing Same, Use Thereof as Drugs, Pharmaceutical Compositions and Novel Use Especially as c-MET Inhibitors | MET, KIT, MERTK | ABL1 6/4885RIPK3 4391/4885RIPK1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.